Loading lessons…
Loading lessons…
Curated lessons across 8 learning paths — from first concepts to trial summaries and practical protocols. Pick your level, follow the curriculum, and build real understanding.
Where are you starting?
Choose a learning path below or search the library. Progress saves in your browser.
Prefer timeline chaos? Peptide X Quiz · Literacy certify
Pick a track — progress rings update as you complete lessons.
6 lessons
9mTirzepatide is the dual GIP/GLP-1 receptor agonist behind Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea). Here's what it is, what the trials showed, how it compares with semaglutide and retatrutide, and how to get evaluated by a licensed clinician.
7mTwo of Lilly's next obesity drugs work in completely different ways. Here's how eloralintide (amylin) and retatrutide (triple agonist) compare on the published data.
9mPeople do not stay on GLP-1 plans because they are disciplined forever. They stay on them when the plan feels manageable, repeatable, and clear enough to trust on a busy week.
8mFinished your GLP-1 cycle and want to maintain metabolic momentum? MOTS-C is one of the most effective peptides for supporting fat oxidation and energy during GLP-1 off-cycles. Here's how to dose and time it.
9mFor years, GLP-1 therapy meant a weekly injection. The FDA just changed that. Foundayo is the first oral GLP-1 approved for weight management, and the implications for the peptide community go far beyond convenience.
11mExplore how Semaglutide has revolutionized weight management through GLP-1 receptor agonism.
Also available at /blog for legacy links.